Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 307.50M | 241.90M | 380.70M | 91.20M | 291.10M |
| Total Depreciation and Amortization | 44.90M | 42.70M | 40.90M | 42.70M | 39.20M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 201.30M | 235.80M | 105.60M | 62.70M | 74.60M |
| Change in Net Operating Assets | 16.60M | 131.50M | -483.40M | 254.30M | 168.80M |
| Cash from Operations | 570.30M | 651.90M | 43.80M | 450.90M | 573.70M |
| Capital Expenditure | -63.60M | -66.90M | -64.90M | -97.40M | -57.50M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 1.40M | -35.10M | -- | -- |
| Divestitures | -- | -- | -- | 42.50M | -- |
| Other Investing Activities | -192.80M | -127.70M | 7.20M | -143.40M | -370.30M |
| Cash from Investing | -256.40M | -193.20M | -92.80M | -198.30M | -427.80M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 36.50M | 53.80M | 68.90M | 32.30M | 34.70M |
| Repurchase of Common Stock | -138.90M | -53.30M | -521.80M | -40.60M | -538.70M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.60M | -800.00K | 1.70M | -3.10M | -236.10M |
| Cash from Financing | -100.80M | -300.00K | -451.20M | -11.40M | -740.10M |
| Foreign Exchange rate Adjustments | -10.40M | 3.80M | 8.20M | 3.50M | -1.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 202.70M | 462.20M | -492.00M | 244.70M | -595.20M |